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Background: Axonal sensory peripheral neuropathy is the major dose-limiting side effect of paclitaxel.Omega-3
fatty acids have beneficial effects on neurological disorders from their effects on neurons cells and inhibition of
the formation of proinflammatory cytokines involved in peripheral neuropathy.
Methods: This study was a randomized double blind placebo controlled trial to investigate the efficacy of omega-3
fatty acids in reducing incidence and severity of paclitaxel-induced peripheral neuropathy (PIPN). Eligible patients
with breast cancer randomly assigned to take omega-3 fatty acid pearls, 640 mg t.i.d during chemotherapy with
paclitaxel and one month after the end of the treatment or placebo. Clinical and electrophysiological studies were
performed before the onset of chemotherapy and one month after cessation of therapy to evaluate PIPN based
on "reduced Total Neuropathy Score".
Results: Twenty one patients (70%) of the group taking omega-3 fatty acid supplement (n = 30) did not develop
PN while it was 40.7%( 11 patients) in the placebo group(n = 27). A significant difference was seen in PN incidence
(OR = 0.3, .95% CI = (0.10-0.88), p = 0.029). There was a non-significant trend for differences of PIPN severity
between the two study groups but the frequencies of PN in all scoring categories were higher in the placebo
group (0.95% CI = (−2.06 -0.02), p = 0.054).
Conclusions: Omega-3 fatty acids may be an efficient neuroprotective agent for prophylaxis against PIPN.
Patients with breast cancer have a longer disease free survival rate with the aid of therapeutical agents. Finding
a way to solve the disabling effects of PIPN would significantly improve the patients’ quality of life.
Trial registration: This trial was registered at ClinicalTrials.gov (NCT01049295)
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Paclitaxel is one of the taxane-derived chemotherapeutic
agents used for treatment of solid tumors including
those of the breast, ovary, lung, and Kaposi’s sarcoma.
It was originated from the Pacific yew Taxus brevifolia.
Paclitaxel is an antimicrotubular agent that polymerizes
tubulin, resulting in formation of stabilized disordered
microtubules without dynamic instability that holds up
cell division [1,2].
Paclitaxel-induced peripheral neuropathy (PIPN) is the
major dose-limiting side effect of paclitaxel [2]. The pre-
cise pathology of PIPN is not fully understood. Paclitaxel
induces an axonal sensory peripheral neuropathy (PN)
as a result of aggregation of microtubules in axons and
Schwann cells. It may also cause fiber demyelination in
some severs cases [1].
Signs of paclitaxel neurotoxicity usually take three
weeks to appear, mainly affecting the sensory, rather
than motor or autonomic nervous systems. The most
common symptoms of PIPN include numbness, tingling,
paresthesias, and a burning pain in a stocking-glove dis-
tribution. The onset of symptoms is often in hands and
feet simultaneously, and some patients complain of facial
discomfort [3,4].
Omega-3 fatty acids eicosapentaenoic acid ( EPA)
and docosahexaenoic acid (DHA) are polyunsaturated
fatty acids(PUFAs) incorporated into the phospholipid
membrane of cells including those of the central and
peripheral nervous systems [5]. They have many benefi-
cial effects in some psychiatric and neurodegenerative
diseases. They determine the biophysical properties of
neuronal membranes and regulate signal transduction by
their effect on ion channels and receptor functions [6].
Moreover, the production of proinflammatory cytokines
which induce neuropathy is attenuated by EPA and
DHA, in particular DHA [5,6]. DHA-induced myelino-
genesis has been reported in the previous studies [7].
Most adverse effects associated with chemotherapy are
ameliorated after cessation of the therapy, but PN maybe
partly reversible or even irreversible in some patients
and as such can significantly decrease the patients’ qual-
ity of life. Taken together, we designed a randomized
placebo-controlled trial to evaluate the possible effect of
omega-3 fatty acid supplementation on PIPN in patients
with breast cancer. To our knowledge, there have been
no previous studies done to demonstrate the possible
effects of omega-3 fatty acid supplementation on PIPN.
Methods/design
Trial design
This study was a randomized double blind placebo-
controlled trial. Subjects were recruited for the study
from April, 2010 to October 2011 from Sheiqorrais
University Clinic. The study protocol was approved bythe ethical committee of Tehran University of Medical
Sciences (No: 9683). Figure 1 shows a summary of the
study design.
Patient selection
Eighty patients were enrolled in the study .Eleven
patients were excluded before randomization, 6 patients
did not meet the inclusion criteria and 5 patients
declined to participate. Therefore, 69 patients were ran-
domly allocated to receive omega-3 fatty acids (n = 35)
or placebo (n = 34). Four patients discontinued the study
due to a critical health conditions and 8 patients were
unwilling to continue after the first cycle of therapy (lost
to follow up, n = 12). So 57 female patients completed
the study (Figure 1). Inclusion criteria were: being
female, age between 30 to 70 years, treatment with 4
courses of 175 mg/m2 paclitaxel for a positive node
breast cancer, satisfactory kidney and liver function,
and WHO performance scores of 0 to 1. All factors
which predisposed patients to PN including a medical
history of prior chemotherapy treatment, pre-existing
peripheral neuropathy due to diabetes mellitus, HIV, al-
cohol abuse, thyroid dysfunction and hereditary PN
associated disorders, and taking any form of nutritional
supplement (fish oil, vitamins and minerals) at least
three months before enrollment were exclusion criteria.
Written informed consent was obtained from all the
patients before any intervention.
Randomization and treatment
Eligible enrolled patients were randomly assigned to re-
ceive omega-3 fatty acid oral supplements as soft gelatin
capsules (Mor DHA Mini I.Q. Minami Nutrition NV,
Drie Eikenstraat 661,2650 Edegem, Belgium) at a dose of
640 mg (54% DHA, 10% EPA) three times a day during
chemotherapy with paclitaxel and one month after the
end of therapy or placebo of Sun flower soft gelatin cap-
sules, (Dana Pharma, Tabriz, Iran) that were similar in
appearance to omega-3 fatty acid soft gelatin capsules
and similarly administered. All patients treated with
paclitaxel (EbetaxelW,Ebewe Pharmaceutical Company,
Austria), at a dose of 175 mg/m² given over a 3-hour
infusion every three weeks for 4 cycles.
The randomization plan was based on a permuted
block randomization. Sealed closed envelopes containing
random codes (A or B) were used to assign subjects
to either the intervention group or the control group.
The allocation of patients was only known to the
randomization coordinator of the study.
Follow up
Primary outcome measures
All the study patients were evaluated both pre-chemotherapy
and one month after the end of chemotherapy by the
Enrolled patients (n=80) 
Excluded (n= 11) 
•   Not meeting inclusion criteria (n= 6) 
•  Declined to participate (n=5 ) 
Data analysis & interpretation (n=30) 
• Neurological & Laboratory assessment 
   before chemotherapy and one month after  
    the cessation of therapy  
 Lost to follow up (n= 5) 
 • Withdrew after one cycle of chemotherapy 
   (n=2) 
 • Discontinued intervention because of critical  
   conditions (n=3) 
Allocated to receive omega-3 fatty acids 
during chemotherapy with paclitaxel and one 
month after the cessation of therapy (n= 35) 
• Neurological & Laboratory assessment 
   before chemotherapy with paclitaxel and  
   one month after the cessation of therapy  
Lost to follow up (n= 7) 
 • Withdrew after one cycle of chemotherapy 
   (n=6) 
 • Discontinued intervention because of critical  
   conditions (n=1) 
Allocated to receive placebo during 
chemotherapy with paclitaxel and one month 
after the cessation of therapy (n= 34) 






Figure 1 Flow diagram of the study design.
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ation and electrophysiologic studies and the patients’allo-
cation to study groups was concealed to him. Reduced
Total Neuropathy Score (rTNS) was used to evaluate
the existence and severity of PIPN in patients as the pri-
mary outcome measures. rTNS consists of subjective
sensory symptoms, pin sensibility, deep tendon reflexes,
and nerve conduction studies of sural and peroneal
nerves, ranging from 0–28 points. Any changes in para-
meters under evaluation in the tests were given a score
from 0 to 4 (depending on the measured severity). By
adding these seven scores together an “rTNS” score
from 0 to 28 was obtained for each patient. The sev-
erity of PIPN then was graded as follows: mild (total
score 1–10), moderate (total score 11-19); and severe
(total score 20–28). rTNS can be easily applied in clinical
settings [8]. rTNS included all the TNS items except
those for motor symptoms, autonomic symptoms, and
quantitative sensory testing of the vibration threshold
[8]. These three items were excluded based on the fol-
lowing: 1) probability of occurrences with paclitaxel
chemotherapy [3,4,9], and 2) the availability of the
necessary device for the examination.Secondary outcome measures
Nerve conduction study
Nerve conduction studies were conducted unilaterally
(right side), using a Nicolet/ VIASYS Viking Quest EMG
Machine based on standard methods [10]. Distal motor
latency (DML), peak to baseline amplitude of compound
muscle action potential (a-CMAP), and motor conduc-
tion velocity were measured for tibial, peroneal, and
ulnar nerves as the motor conduction assessment.
Sensory nerve conduction of sural and ulnar nerves was
evaluated with peak-to-peak amplitude measurement of
sensory action potentials (a-SAP) and sensory conduc-
tion velocity (antidromic technique).
Serum levels of omega-3 fatty acids
Concentrations of EPA and DHA in serum phos-
pholipids were measured by gas liquid chromatography
using the method described by Noori M and his col-
leagues [11].
Statistical analysis
Data were summarized using mean (SD) and frequency
(percent) for quantitative and qualitative variables respectively.
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ences of nerve conduction measurements and the serum
phospholipids concentrations of omega-3 fatty acids
between the two study groups, adjusting baseline mea-
surements. To investigate the difference of PN incidence
between the omega-3 supplemented group and the con-
trol group, logistic regression performed to estimate the
odds ratio. Ordinal regression analysis was used to com-
pare the severity of PN between the two study groups.
All tests were two-sided and significance level was set at
0.05. Statistical power of the study was considered as
80% [12]. Analysis was done using spss software, (spss
Inc., Chicago, IL).
Sample size
Sample size was determined based on primary information
obtained from the study by Okuda et. al [13] for vibratory
perception threshold(VPT): By considering α = 0.05 and
a power of 80%, the sample size was computed as
23.24 (24) per group [12]. This number was increased
to 28 per group to accommodate the anticipated 20%
dropout rate, although more patients were enrolled.
Results
Fifty seven female breast cancer patients were randomly
assigned to either the omega-3 supplemented group
(n = 30) or the placebo group (n = 27). From now on we
pointed out the omega-3 supplemented group as group I
and the placebo group as group II. The mean age of
group I was 46.19 ± 9.76 and it was 45.70 ± 12.00 for
group II. There was no statistical significant difference
between the two groups according to age (P = 0.86). The
means of body mass index (BMI) for the omega-3 sup-
plemented group and the control group were 45.99 ±
9.01 and 44.14 ± 8.89 respectively, without statistical dif-
ferences (p = 0.43). All the patients treated with 4
courses of 175 mg/m2 paclitaxel for a positive node
breast cancer. They all had a satisfactory kidney and
liver function, and WHO performance scores of 0 to 1.
Peripheral neuropathy
The “reduced Total Neuropathy Score (rTNS)” of the 30
patients in group I was as follows: 21 patients (70%) did
not develop PN and 9 patients (30%) manifested some
grade of neurotoxicity: Four patients (13.3%) developed
mild PN; five patients (16.7%) developed moderate PN
and sever PN was not observed in this group of study
subjects (Table 1).
In group II, PN was not revealed in 11 patients
(40.7%), while 10 patients (37%) developed mild PN and
5 patients (18.5%) developed moderate PN. Also, severe
neuropathy was seen in one patient (3.7%) (Table 1). A
significant difference was observed between the omega-3
supplemented group and the placebo group in PNincidence (OR = 0.3, .95% CI = (0.10-0.88), p = 0.029).
So group I had 70% lower risk of PN incidence. The
number needed to treat (NNT) to prevent one PN event
was 3. In addition, there were not statistically significant
differences in severity of PN between these two groups
(B = −1.02, .95% CI = (−2.06 - 0.02), p = 0.054).
Nerve conduction study parameters
Using analysis of covariance adjusting baseline measure-
ments to determine the differences of quantitative values
between two study groups, a significant difference of
sural a-SAP was observed between the omega-3 supple-
mented group and the control (p = 0.015) with a sharp
decrease of sural a-SAP in the placebo group. The other
differences of NCS parameters did not reach statistical
significance (Table 2 and 3).
Serum levels of omega-3 fatty acids
Serum phospholipid concentrations of EPA and DHA
were significantly different between the omega-3 supple-
mented group and the placebo group (P = 0.005 and P =
0.001 respectively): in the omega-3 supplemented group,
EPA concentrations increased from 0.53 ± 0.32 at the
baseline to 0.61 ± 0.37 at the end of the intervention and
DHA concentrations changed from 0.64 ± 48 at the base-
line to 1.05 ± 0.79 after the cessation of supplementation
with omega-3 fatty acids. In the placebo group, mea-
sured changes were 0.63 ± 0.39 to 0.59 ± 0.41 for EPA
and 0.71 ± 0.54 to 0.63 ± 0.33 for DHA serum levels, re-
spectively. No statistically significant differences were
observed between the two study groups in incidence and
severity of the PIPN according to the changes of serum
DHA and EPA levels.
Discussion
Cumulative neurotoxicity along with axonal disorders
are common in PIPN [3]. The cellular microtubules of
malignant cells and axons of peripheral nerves are the
targets of paclitaxel and it inhibits tubulin depoly-
merization [4]. It was estimated that 60%-70% of
patients who received this chemotherapeutic agent
developed dose-dependent neurotoxicity [4,14].
The aim of the current double-blind placebo-con-
trolled trial was to trace the efficacy of omega-3 fatty
acids (mainly DHA), in prophylaxis against paclitaxel
induced neurotoxicity. To do this, eligible patients with
node positive breast cancer undergoing chemotherapy
with paclitaxel were randomly assigned to take oral sup-
plements of omega-3 fatty acids or a placebo during the
course of their therapy cycles and one month after the
end of chemotherapy.
There was a significant difference in PIPN incidence
between the two study groups so that 70% of patients
taking omega-3 fatty acid supplements did not develop
Table 1 Paclitaxel-induced peripheral neuropathy in the study groups
Peripheral neuropathy
Normal Mild Moderate Severe Total
Omega- 3 supplemented group 21(70%) 4(13.3%) 5(16.7%) 0% 30(100%)
Placebo received group 11(40.7%) 10(37%) 5(18.5%) 1(3.7%) 27(100%)
A significant difference in PN incidence (OR = 0.3, .95% CI = (0.10 - 0.88), p = 0.029).
No significant difference in severity of PN (B = −1.02, .95% CI = (−2.06 - 0.02), p = 0.054).
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seems that omega-3 fatty acids, in particular DHA, had
neuroprotective effects and that they decreased the
paclitaxel-associated neurotoxicity considerably. Our
results are in accordance with previous studies that have
investigated the efficacy of these fatty acids in diabetic
neuropathy. They showed that omega-3 fatty acids could
attenuate the severity of neuropathy in patients with
type 2 diabetes mellitus [13,15]. They also prevented the
lowering of nerve conduction velocity in the sciatic
nerve of diabetic rats by improving the activity of
Na+/K +ATPase [16]. There was a considerable trend
that did not reach significance for the differences of
PIPN severity between group I and II, while the frequen-
cies of PN were higher in the placebo group almost inTable 2 Motor nerve conduction measurements
group Pre-chemothe
Tibial nerve
DML(ms) Omega 3 16.53 (1.95)
Placebo 17.00 (2.16)
a-CMAP(mV) Omega 3 10.00 (5.18)
Placebo 11.38 (6.08)
MCV(m/s) Omega 3 46.38 (3.67)
Placebo 46.24 (5.08)
Peroneal nerve
DML(ms) Omega 3 14.16 (1.80)
Placebo 14.85 (3.18)
a-CMAP(mV) Omega 3 6.20 (6.68)
Placebo 5.51 (3.41)
MCV(m/s) Omega 3 46.13 (3.32)
Placebo 46.46 (5.24)
Ulnar nerve
DML(ms) Omega 3 9.48 (.74)
Placebo 9.67 (.98)
a-CMAP(mV) Omega 3 17.29 (12.95)
Placebo 13.80 (3.53)
MCV(m/s) Omega 3 57.30 (5.18)
Placebo 55.80 (4.90)
DML, distal motor latency; a-CMAP, amplitude of compound muscle action potentia
* One month after the cessation of chemotherapy.
# p value is reported based on the analysis of covariance.all scoring categories (Table 1) and severe neuropathy
was not seen in the omega-3 supplemented group.
Neurophysiologic studies improve the accuracy and
precision of peripheral neuropathy evaluation and help
to identify patients at risk of peripheral neuropathy even
before the onset of clinical symptoms [4,17]. rTNS is a
composite scale used to assess the incidence and severity
of PIPN that can be easily used in the research and clin-
ical centers [8]. Generally, rTNS is well correlated with
the oncologic toxicity scales including National Cancer
Institute- Common Toxicity Criteria (NCI-CTS), Eastern
Cooperative Oncology Group (ECOG), Ajani, and the
extended TNS version with these additional parameters:
motor symptoms, autonomic symptoms and quantitative



















l; MCV, motor conduction velocity.
Table 3 Sensory nerve conduction measurements
Group Pre-chemotherapy Post-chemotherapy* p-value#
Sural nerve
a-SAP(μV) Omega 3 13.27 (5.02) 13.33 (5.91) .015
Placebo 13.70 (7.46) 9.74 (5.96)
SCV(m/s) Omega 3 54.35 (7.13) 54.79 (8.35) .514
Placebo 53.50 (6.79) 52.52 (8.05)
Ulnar nerve
a-SAP(μV) Omega 3 34.23 (14.85) 24.53 (13.95) .454
Placebo 31.15 (14.02) 21.53 (13.70)
SCV(m/s) Omega 3 57.30 (5.18) 55.82 (6.35) .212
Placebo 55.80 (4.90) 53.19 (7.29)
a-SAP, sensory action potential amplitude; SCV, sensory conduction velocity.
* One month after the cessation of chemotherapy.
# p value is reported based on the analysis of covariance.
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significant changes of nerve conduction velocity as it
was seen in this study and these changes are indicators
of axonal dysfunction rather than myelin disorders [4].
In the current study, a considerable difference was
observed in sural nerve a-SAP between the two groups
with a sharp decrease in the placebo group. Argyriou
et al. [18], evaluated the role of clinical and NCS mea-
surements to predict the outcomes of CIPN. They found
that only the decrease of the sural a-SAP was associated
with the worse neurological outcomes. Our results
showed that omega-3 fatty acids prevented the signifi-
cant decrease of sural nerve a-SAP in group I that
it may be related to their ability of PIPN reduction in
this group.
Previous studies have shown that there are no known
pharmacologic agents to prevent or to cure PN in cancer
patients. In recent years, the efficacy of some vitamins
and minerals, amino acids, cytokines, carnitines, antide-
pressants and anticonvulsants have been tested [19].
Vitamin E, acetyl-L carnitine, and glutamine are among
the oral supplements which have been studied to pre-
vent or attenuate PIPN, but they were not evaluated in
large randomized placebo-controlled trials or they had
little success in this regard [19]. An ideal neuroprotec-
tive agent for prophylaxis against PIPC should be safe
for the patients without reducing the efficacy of the ther-
apy, DHA may be the answer.
Growing evidences have demonstrated the positive
influences of omega-3 fatty acids in the prevention of a
wide range of psychiatric, arrhythmic, and neurological
disorders such as Alzheimer’s and Parkinson’s diseases,
major depression. schizophrenia and dementia. Omega-3
fatty acids are a branch of long chain polyunsaturated
fatty acids, originated from marine and plant sources. By
incorporating into the neuronal cell membranephospholipids, they influence critical membrane-
associated functions like signal transduction, ion channel
dependent transportations (via voltage-dependent so-
dium channels and L-type calcium channels), receptors
physiological properties, and neurotransmission [6,20].
In addition to their direct effect on neuropathic pain,
omega-3 fatty acids inhibit the production of proinflam-
matory cytokines associated with neuropathic pain (i.e.,
IL-1β, IL-6, and TNF-α) [5], and the role of DHA in
myelogenesis has been documented in the previous stud-
ies [6,7,20]. Lauretania F et.al, have shown that DHA was
an effective agent that improved axonal degeneration in
the patients [20]. In another study accomplished by
Ward R et.al, DHA had a significant neuroprotective role
in the axonal damage due to spinal cord injury [21]. With
respect to DHA, it was conjugated with paclitaxel to
form DHA-paclitaxel, a taxane-fatty acid conjugate with
intratumoral activation. DHA-paclitaxel was more effi-
cient treating cancer and caused significantly less toxicity
over existing paclitaxel [22]. In addition, neurotoxicity
may be prevented by cox-2 inhibition [23] and omega-3
fatty acids inhibit the generation of cox-2 mRNA [24].
US Food and Drug Administration (FDA) has recom-
mended that a total maximum dose of 3 grams per day
of DHA and EPA omega-3 fatty acids can be safely con-
sumed [25]. In this study, the total dose of omega-3 fatty
acids administered was 1244.1 mg per day (640 mg: 54%
DHA, 10% EPA, three times a day) which was far below
the maximum daily allowance of omega-3 fatty acids
consumption for more caution. Although in a number of
placebo-controlled prospective trials no considerable ad-
verse effects were reported of omega-3 fatty acids, to
prevent patients from experiencing nausea and gastro-
intestinal disturbances, they were advised to take fish oil
pearls with meals and to keep them in a freezer [25].
There was a dramatic increase of serum concentrations
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supplements and a significant difference was observed
between two the study groups in terms of this issue,
which could be an indicator of participant compliance.
Conclusions
Although the survival rate of breast cancer patients
improved by significant advances in treatment strategies,
disabling and dose-limiting peripheral neuropathy due to
chemotherapy with paclitaxel decreases the patients’
quality of life and sometimes forces the oncologist to
change or even end the treatment [18]. No standard
therapeutic agent exists for the prevention or treatment
of chemotherapy-induced neuropathy [19]. Thus, finding
a novel neuroprotective agent seems to be critical.
Omega-3 fatty acids were efficient for prophylaxis
against PIPN in this study. According to our knowledge,
this is the first time that the efficacy of omega-3 fatty
acids has been assessed for their ability to reduce inci-
dence and severity of PIPN.
There were some limitations in the design of this
double-blind placebo-controlled randomized trial. The
lack of long term follow up of outcomes measured was a
potential limitation of the study. In addition, Sun flower
soft gelatin capsules used as placebo had no fishy taste,
and the psychological status of the patients was not eval-
uated in this study although it may has been affected by
omega-3 fatty acids. Relatively small sample size was
another possible limitation of the current trial.
Polymorphisms of corresponding cytochrome P-450
enzymes could influence the paclitaxel clearance and
drug-related side effects [17]. Therefore, genotyping
could help to identify those cancer patients who are at
risk of developing neurotoxicity so that they may be
advised to take neuroprotectant supplements before the
onset of painful and disabling PIPN. The effectiveness
of omega-3 fatty acids supplementation for neuropro-
tection of patients with breast cancer treated with pacli-
taxel is supported by results from the present study.
Another double-blind placebo-controlled randomized
clinical trial with larger sample size is needed to confirm
these findings.
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